Nektar Therapeutics held its Annual Meeting of Stockholders on May 23, 2025. During the meeting, several proposals were addressed. The election of Diana Brainard and R. Scott Greer to the board of directors was approved. An amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance by 6,000,000 shares was approved. An amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 390,000,000 shares was approved. Additionally, an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-40, at the discretion of the Board, was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.